Log in

Relevant bibliographies by topics / Adjuvant treatment / Journal articles

Journal articles on the topic 'Adjuvant treatment'

To see the other types of publications on this topic, follow the link: Adjuvant treatment.

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Adjuvant treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hauschild and Volkenandt. "Adjuvant treatment of malignant melanoma." Therapeutische Umschau 56, no. 6 (June 1, 1999): 324–29. http://dx.doi.org/10.1024/0040-5930.56.6.324.

Full text

Abstract:

Das Ziel einer adjuvanten Therapie nach operativer Entfernung eines Melanoms besteht in der Unterdrückung der Ausbreitung eventuell vorhandener, klinisch inapparenter Mikrometastasen. Vergleiche verschiedener Therapieverfahren (z.B. adjuvant applizierte Chemotherapeutika) mit unbehandelten Kontrollkollektiven ließen in der Vergangenheit gelegentlich eine Wirksamkeit erhoffen. Große, multizentrische, kontrollierte und prospektiv randomisierte Studien konnten jedoch keinen eindeutigen Vorteil einer adjuvanten Chemotherapie in bezug auf die Verlängerung der rezidivfreien Überlebenszeit oder der Gesamtüberlebenszeit erkennen. Eine adjuvante Zytostatika-Therapie kann daher außerhalb von klinischen Studien derzeit nicht mehr empfohlen werden. Derzeitige Hoffnungsträger sind insbesondere die rekombinant herstellbaren Zytokine, vor allem die Interferone. Drei große und randomisierte Studien zur adjuvanten Therapie mit Interferon-alpha von Hochrisiko-Patienten zeigten übereinstimmend eine verbesserte rezidivfreie Überlebenszeit; der Einfluß der Interferon-alpha-Behandlung auf die Heilungsraten bleibt jedoch weiterhin unklar. Ebenso kann derzeit zur optimalen Dosis und Dauer der Interferon-alpha-Therapie noch nicht eindeutig Stellung bezogen werden. Melanom-Patienten mit einem hohen Metastasierungsrisiko sollten in nationale und internationale prospektiv-randomisierte Therapieprotokollen eingeschlossen werden, deren Ergebnisse zu allgemeinverbindlichen Empfehlungen zur adjuvanten Melanomtherapie führen können.

APA, Harvard, Vancouver, ISO, and other styles

2

Le Chevalier, Thierry. "Adjuvant treatment." American Journal of Cancer 3, Supplement 2 (2004): 3–5. http://dx.doi.org/10.2165/00024669-200403992-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sultana, Asma, John Neoptolemos, and Paula Ghaneh. "Adjuvant treatment." HPB 8, no. 5 (October 2006): 352–64. http://dx.doi.org/10.1080/13651820600804146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Snipes, C. E., and G. D. Wills. "Influence of Temperature and Adjuvants on Thidiazuron Activity in Cotton Leaves." Weed Science 42, no. 1 (March 1994): 13–17. http://dx.doi.org/10.1017/s0043174500084095.

Full text

Abstract:

A laboratory study was conducted to determine the effects of two adjuvants and temperatures at time of treatment on efficacy, absorption, and translocation of thidiazuron defoliant on cotton. Five days after treatment at 30/21 C day/night temperatures, leaf drop was 17% with no adjuvant, 37% with addition of crop oil concentrate, 40% with ammonium sulfate, and 75% with two adjuvants combined. At 21/13 C day/night temperatures, there was less than 10% leaf drop with all treatments. At 10 d after treatment, leaf drop was not different among treatments at the high or low temperatures. Shoot regrowth at high and low temperature was reduced 55 to 60% with addition of both adjuvants and 44 to 50% with each adjuvant or with no adjuvant when compared to plants defoliated by hand. Absorption of14C-thidiazuron was not affected by variations in temperature during the time of treatment but was affected by adjuvants. With no adjuvants, absorption was 7 to 10%. With 1.25% by vol crop oil concentrate, absorption was 33 to 46%. Addition of ammonium sulfate resulted in 18 to 19% absorption, and the combination of ammonium sulfate and crop oil concentrate increased absorption to 65 to 68%. There was no movement of radiolabel away from treated leaves as determined by autoradiographs of treated plants.

APA, Harvard, Vancouver, ISO, and other styles

5

Garcia, Luiz C., Guilherme H. Carraro, Sandro Felema, Allison J. Fornari, Leandro J. V. Sformi, and Thiago M. Inagaki. "Adjuvants used in fungicide spraying on soybean plants." Spanish Journal of Agricultural Research 22, no. 3 (June 13, 2024): e1003. http://dx.doi.org/10.5424/sjar/2024223-20497.

Full text

Abstract:

Aim of study: An adjuvant is a material that is added to a spray carrier to improve the application technology's efficiency but lacks phytosanitary qualities. Our objective was to determine the best option of combining fungicides and adjuvants to control soybean (Glycine max) leaf diseases in three cropping seasons. Area of study: The experiment was developed in the Campos Gerais region (PR - Brazil). Material and methods: The five treatments consisted of 1) control (without applying fungicides on soybean plants); 2) fungicide application on soybean plants without adjuvant; 3) fungicide with adjuvant based on mineral oil; 4) fungicide with adjuvant based on lecithin and 5) propionic acid and fungicide with 50% of the dose of adjuvant based on mineral oil + 50% of the dose of surfactant adjuvant based on lecithin and propionic acid. The analyzed variables were the physicochemical characteristics of the spray carrier, the incidence and severity of diseases, and the yield components. A completely randomized design was used to study the physicochemical characteristics of the carrier and in randomized blocks for the field experiment. We used five replicates per treatment. Main results: No foaming and mixing incompatibility of the spray carrier was observed in any treatment. The adjuvant based on lecithin and propionic acid further acidified the spray carrier and presented the same surface tension as mineral oil. The soybean plants that did not receive chemical treatment had a higher occurrence of diseases, which reduced the productive potential. Research highlights: Adding adjuvants to the spray carrier did not increase the performance of fungicides in controlling diseases and did not affect the yield components.

APA, Harvard, Vancouver, ISO, and other styles

6

Pujisiswanto, Hidayat, Yayuk Nurmiaty, Nanik Sriyani, and Annisa Efrima. "Pengaruh Ekstrak Buah Lerak (Sapindus rarak) dan Beberapa Adjuvan terhadap Perkecambahan Gulma Fimbristylis miliacea." JURNAL AGROTROPIKA 20, no. 2 (October 3, 2021): 104. http://dx.doi.org/10.23960/ja.v20i2.5205.

Full text

Abstract:

Adjuvant is an ingredient added in a formulation to increase the effectiveness of lerak fruit in inhibiting weeds. This study aims to determine the type of adjuvant in lerak fruit extract that can increase the inhibition of germination of Fimbristylis miliacea and to determine the type of adjuvant in lerak fruit extract that is most effective in inhibiting the germination of F. miliacea. The research was conducted from December 2019 to March 2020 in the Weed Laboratory, Faculty of Agriculture, University of Lampung. This study used a Completely Randomized Design (CRD) to determine the type of adjuvant given to lerak fruit extract on F. miliacea germination with 4 replications. The treatments consisted of lerak fruit extract, lerak fruit extract + VCO adjuvant, lerak fruit extract + KAO adjuvant, lerak fruit extract + Polysorbate 80 adjuvant, and control. The Bartlett test was used to test the homogeneity of variance, if the assumptions of the analysis of variance were met, then the mean value of the treatment was continued with the Least Significant Difference (LSD) test at the 5% level. The results showed that adjuvants and without adjuvants added to lerak fruit extract at a concentration of 50% (500 g/l) were able to suppress the percentage of germination and the speed of germination of Fimbristylis miliace seeds.Keywords: adjuvants, lerak fruit extract, Fimbristylis miliacea, weed

APA, Harvard, Vancouver, ISO, and other styles

7

Boccon-Gibod, Laurent. "Adjuvant treatment to surgery." BJU International 100, s2 Prostate Can (July 2007): 40–43. http://dx.doi.org/10.1111/j.1464-410x.2007.06953.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Moreno Nogueira, J. A., M. Valero Arbizu, and R. Pérez Temprano. "Adjuvant Treatment of Melanoma." ISRN Dermatology 2013 (February 17, 2013): 1–17. http://dx.doi.org/10.1155/2013/545631.

Full text

Abstract:

Melanomas represent 4% of all malignant tumors of the skin, yet account for 80% of deaths from skin cancer.While in the early stages patients can be successfully treated with surgical resection, metastatic melanoma prognosis is dismal. Several oncogenes have been identified in melanoma as BRAF, NRAS, c-Kit, and GNA11 GNAQ, each capable of activating MAPK pathway that increases cell proliferation and promotes angiogenesis, although NRAS and c-Kit also activate PI3 kinase pathway, including being more commonly BRAF activated oncogene. The treatment of choice for localised primary cutaneous melanoma is surgery plus lymphadenectomy if regional lymph nodes are involved. The justification for treatment in addition to surgery is based on the poor prognosis for high risk melanomas with a relapse index of 50–80%. Patients included in the high risk group should be assessed for adjuvant treatment with high doses of Interferon-α2b, as it is the only treatment shown to significantly improve disease free and possibly global survival. In the future we will have to analyze all these therapeutic possibilities on specific targets, probably associated with chemotherapy and/or interferon in the adjuvant treatment, if we want to change the natural history of melanomas.

APA, Harvard, Vancouver, ISO, and other styles

9

Rubens, R. D. "Breast cancer: Adjuvant treatment." European Journal of Cancer 28, no. 2-3 (February 1992): 620–22. http://dx.doi.org/10.1016/s0959-8049(05)80111-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sehati, Nouzhan, and Linda M. Liau. "Adjuvant Treatment for Gliomas." Contemporary Neurosurgery 25, no. 15 (July 2003): 1–9. http://dx.doi.org/10.1097/00029679-200307310-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Baum, M., and J. Cuzick. "Adjuvant treatment with tamoxifen." BMJ 312, no. 7037 (April 20, 1996): 1036. http://dx.doi.org/10.1136/bmj.312.7037.1036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Bulbrook, R. D. "Adjuvant treatment with tamoxifen." BMJ 313, no. 7055 (August 24, 1996): 493–94. http://dx.doi.org/10.1136/bmj.313.7055.493c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

McClellan, M. B. "Adjuvant Breast Cancer Treatment." JAMA: The Journal of the American Medical Association 288, no. 17 (November 6, 2002): 2112—a—2112. http://dx.doi.org/10.1001/jama.288.17.2112-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

McClellan, Mark B. "Adjuvant Breast Cancer Treatment." JAMA 288, no. 17 (November 6, 2002): 2112. http://dx.doi.org/10.1001/jama.288.17.2112-jfd20011-2-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Andrade Santos, Caique, Rafael Sponchiado Cavallieri, Fabiano Vieira Vilhena, and Mariana Schutzer Ragghianti Zangrando. "Adjuvant use of Phtalox in sport lip injury treatment." International Journal of Case Reports and Images 14, no. 1 (April 14, 2023): 80–83. http://dx.doi.org/10.5348/101388z01cs2023ci.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Osorio, Marlon, Estefanía Martinez, Tonny Naranjo, and Cristina Castro. "Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review." Molecules 25, no. 10 (May 12, 2020): 2270. http://dx.doi.org/10.3390/molecules25102270.

Full text

Abstract:

Colorectal cancer (CRC) is the type with the second highest morbidity. Recently, a great number of bioactive compounds and encapsulation techniques have been developed. Thus, this paper aims to review the drug delivery strategies for chemotherapy adjuvant treatments for CRC, including an initial scientific-technological analysis of the papers and patents related to cancer, CRC, and adjuvant treatments. For 2018, a total of 167,366 cancer-related papers and 306,240 patents were found. Adjuvant treatments represented 39.3% of the total CRC patents, indicating the importance of adjuvants in the prognosis of patients. Chemotherapy adjuvants can be divided into two groups, natural and synthetic (5-fluorouracil and derivatives). Both groups can be encapsulated using polymers. Polymer-based drug delivery systems can be classified according to polymer nature. From those, anionic polymers have garnered the most attention, because they are pH responsive. The use of polymers tailors the desorption profile, improving drug bioavailability and enhancing the local treatment of CRC via oral administration. Finally, it can be concluded that antioxidants are emerging compounds that can complement today’s chemotherapy treatments. In the long term, encapsulated antioxidants will replace synthetic drugs and will play an important role in curing CRC.

APA, Harvard, Vancouver, ISO, and other styles

17

Sherrick, Stewart L., Harvey A. Holt, and F. Dan Hess. "Effects of Adjuvants and Environment During Plant Development on Glyphosate Absorption and Translocation in Field Bindweed (Convolvulus arvensis)." Weed Science 34, no. 6 (November 1986): 811–16. http://dx.doi.org/10.1017/s004317450006793x.

Full text

Abstract:

Absorption and translocation of glyphosate [N-(phosphonomethyl)glycine] with and without adjuvants were examined in field bindweed (Convolvulus arvensisL. # CONAR) to develop an understanding of the influence of selected adjuvants and environment before application on glyphosate activity. Light intensity and humidity during plant development resulted in differences in14C-glyphosate absorption. When applied in water or with an oxysorbic (20 POE) (polyoxyethylene sorbitan monolaurate) adjuvant, an average of 9% of the glyphosate was absorbed in plants grown in high light intensity, low humidity (HLLH) before treatment, compared to an average of 21% in plants grown in low light, high humidity (LLHH) before treatment, respectively. Amounts of epicuticular wax on HLLH field bindweed were almost three times as great as on LLHH leaves and may explain absorption differences. No differences in glyphosate absorption were observed between glyphosate applied with oxysorbic or no adjuvant even though the oxysorbic adjuvant effectively reduces surface tension. Absorption was increased two- to threefold with a polyethoxylated tallow amine adjuvant (MON 0818) compared to no adjuvant. Unlike absorption without adjuvant or with oxysorbic adjuvant, there were few absorption differences in plants grown in different environments before application. Absorption continued for 24 to 36 h after application regardless of adjuvant. Reductions in MON 0818 concentration and subsequent necrosis resulted in increased movement of radioactivity away from the site of application.

APA, Harvard, Vancouver, ISO, and other styles

18

Yang, Ya-Wun, and Chih-Feng Chang. "Induction of differentiation of hematopoietic cells by the vaccine adjuvants (75.10)." Journal of Immunology 188, no. 1_Supplement (May 1, 2012): 75.10. http://dx.doi.org/10.4049/jimmunol.188.supp.75.10.

Full text

Abstract:

Abstract Vaccine adjuvants have been used to enhance the immune responses against the co-administered antigens. The mechanisms of action by the adjuvants however remain poorly understood. We attempt to investigate in this study the effect of vaccine adjuvants on differentiation of the hematopoietic system. C57BL/6J mice were vaccinated with ovalbumin (OVA) in L121-adjuvant, an emulsion adjuvant consists of Pluronic L121 that previously shown to stimulate cytotoxic lymphocyte (CTL) effect. Cells were isolated from bone marrow and thymus after vaccination, followed by flow cytometric analysis. Our data showed that treatment of animals with L121-adjuvant skewed the differentiation of hematopoietic cells, resulting in a significant increase of the CD11b+ population at the expense of lineage (lin)+ cells, attributing mainly to a dramatic reduction of the B220+ population. A considerable increase of Lin-/Sca1+/c-Kit+ (LSK) hematopoietic stem/progenitor cells was observed in the bone marrow of immunized mice, suggesting an induction of enhanced cell expansion by the vaccine adjuvant. Treatment of animals with L121-adjuvant also affects the differentiation of cells in the thymus with a decrease of the CD4+/CD8+ double-positive (DP) cells, and a concurrent increase of the CD4+ and CD8+ single positive (SP) populations. These experimental results suggested the differentiation effect of vaccine adjuvants on the hematopoietic system, accounting for the enhanced immunity after immunization.

APA, Harvard, Vancouver, ISO, and other styles

19

Ioannidis, J. "Neo-adjuvant vs adjuvant treatment— evidence from clinical trials." European Journal of Cancer Supplements 4, no. 2 (March 2006): 107. http://dx.doi.org/10.1016/s1359-6349(06)80226-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

D’Hondt, V., and M. Piccart. "Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies." Annals of Oncology 15 (October 2004): iv23—iv29. http://dx.doi.org/10.1093/annonc/mdh901.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wils, J. A. "Adjuvant treatment of colorectal cancer." Acta chirurgica Iugoslavica 49, no. 2 (2002): 15–18. http://dx.doi.org/10.2298/aci0202015w.

Full text

Abstract:

Colorectal cancer is a leading cause of morbidity and mortality, with approximately 300,000 new cases and 200,000 related deaths in Europe and the USA each year. Adjuvant treatment of colorectal cancer is now widely accepted and can reduce mortality with approximately 10%. This can be considered as one of the major achievements in oncology from the past decade. Current results will be discussed and strategies for the future will be outlined, including on-going or planned large-scale trials with new drugs and approaches.

APA, Harvard, Vancouver, ISO, and other styles

22

Klaiber, Ulla, Thilo Hackert, and John P. Neoptolemos. "Adjuvant treatment for pancreatic cancer." Translational Gastroenterology and Hepatology 4 (April 2019): 27. http://dx.doi.org/10.21037/tgh.2019.04.04.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Chu, Edward. "Adjuvant Therapy: New Treatment Options." Clinical Colorectal Cancer 4, no. 4 (November 2004): 219–20. http://dx.doi.org/10.3816/ccc.2004.n.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Wolpin, B. M., J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer. "Adjuvant Treatment of Colorectal Cancer." CA: A Cancer Journal for Clinicians 57, no. 3 (May 1, 2007): 168–85. http://dx.doi.org/10.3322/canjclin.57.3.168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Latif, Jasima, and Shaveta Mehta. "Adjuvant treatment for breast cancer." Surgery (Oxford) 40, no. 2 (February 2022): 132–38. http://dx.doi.org/10.1016/j.mpsur.2021.11.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Vergote, Ignace B. "Adjuvant treatment of ovarian carcinoma." Acta Obstetricia et Gynecologica Scandinavica 72, no. 8 (January 1993): 682–84. http://dx.doi.org/10.3109/00016349309021167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Taal, B. G., H. van Tinteren, and L. van t Veer. "Adjuvant treatment in colorectal cancer." British Journal of Cancer 86, no. 9 (May 2002): 1525–26. http://dx.doi.org/10.1038/sj.bjc.6600280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Saltz, MD, Leonard B., and David P. Kelsen, MD. "ADJUVANT TREATMENT OF COLORECTAL CANCER." Annual Review of Medicine 48, no. 1 (February 1997): 191–202. http://dx.doi.org/10.1146/annurev.med.48.1.191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Conroy, Thierry, and Michel Ducreux. "Adjuvant treatment of pancreatic cancer." Current Opinion in Oncology 31, no. 4 (July 2019): 346–53. http://dx.doi.org/10.1097/cco.0000000000000546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Emons, Günter, and Dirk Vordermark. "Adjuvant treatment for endometrial cancer." Current Opinion in Oncology 31, no. 5 (September 2019): 404–10. http://dx.doi.org/10.1097/cco.0000000000000558.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Smith, R. "Hypnosis--adjuvant in dental treatment." British Dental Journal 160, no. 10 (May 1986): 344. http://dx.doi.org/10.1038/sj.bdj.4805860.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bleiberg, Harry. "Adjuvant treatment of colon cancer." Current Opinion in Oncology 17, no. 4 (July 2005): 381–85. http://dx.doi.org/10.1097/01.cco.0000166648.92674.4c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Passant, Helen, and Annabel Borley. "Adjuvant treatment for breast cancer." Surgery (Oxford) 28, no. 3 (March 2010): 140–43. http://dx.doi.org/10.1016/j.mpsur.2009.11.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Passant, Helen, and Annabel Borley. "Adjuvant treatment for breast cancer." Surgery (Oxford) 31, no. 1 (January 2013): 37–40. http://dx.doi.org/10.1016/j.mpsur.2012.10.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Flatley, Michael J., and David J. Dodwell. "Adjuvant treatment for breast cancer." Surgery (Oxford) 34, no. 1 (January 2016): 43–46. http://dx.doi.org/10.1016/j.mpsur.2015.10.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Flatley, Michael J., and David J. Dodwell. "Adjuvant treatment for breast cancer." Surgery (Oxford) 37, no. 3 (March 2019): 176–80. http://dx.doi.org/10.1016/j.mpsur.2019.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Neoptolemos, John P. "Adjuvant treatment of pancreatic cancer." European Journal of Cancer 47 (September 2011): S378—S380. http://dx.doi.org/10.1016/s0959-8049(11)70210-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Midgley, R. S., and D. J. Kerr. "Adjuvant treatment of colorectal cancer." Cancer Treatment Reviews 23, no. 3 (May 1997): 135–52. http://dx.doi.org/10.1016/s0305-7372(97)90035-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Agarwala, Sanjiv S., and John M. Kirkwood. "ADJUVANT INTERFERON TREATMENT FOR MELANOMA." Hematology/Oncology Clinics of North America 12, no. 4 (August 1998): 823–33. http://dx.doi.org/10.1016/s0889-8588(05)70025-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Beretta, Giordano D., L. Milesi, M. A. Pessi, S. Mosconi, and R. Labianca. "Adjuvant treatment of colorectal cancer." Surgical Oncology 13, no. 2-3 (August 2004): 63–73. http://dx.doi.org/10.1016/j.suronc.2004.09.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Akers, S., B. Khulpateea, A. Groman, J. Kesterson, K. Odunsi, S. Lele, and P. Frederick. "Adjuvant treatment for uterine leiomyosarcoma." Gynecologic Oncology 125 (March 2012): S159. http://dx.doi.org/10.1016/j.ygyno.2011.12.392.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Plowman, P. N., W. H. Allum, TrevorJ Powles, IanE Smith, Barnett Zumoff, A. Y. Rostom, A. R. Gershuny, HelenS Kaplan, and Heather Goodare. "Adjuvant treatment in breast cancer." Lancet 339, no. 8790 (February 1992): 423–24. http://dx.doi.org/10.1016/0140-6736(92)90106-d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Schulz, K. D. "Adjuvant treatment of endometrial carcinoma." Journal of Cancer Research and Clinical Oncology 111, S1 (February 1986): S6. http://dx.doi.org/10.1007/bf02579795.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Macdonald, John S., and Sandra F. Schnall. "Adjuvant treatment of gastric cancer." World Journal of Surgery 19, no. 2 (1995): 221–25. http://dx.doi.org/10.1007/bf00308630.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Gelber, R. D. "Breast cancer and adjuvant treatment." Biomedicine & Pharmacotherapy 48, no. 8-9 (January 1994): 409. http://dx.doi.org/10.1016/0753-3322(94)90067-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Steele, G. "Adjuvant treatment of colorectal adenocarcinoma." Current Problems in Cancer 17, no. 4 (August 1993): 226–69. http://dx.doi.org/10.1016/0147-0272(93)90005-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lise, Mario, Donate Nitti, Alberto Marchet, and Adriano Fornasiero. "Adjuvant treatment for gastric cancer." Anti-Cancer Drugs 2, no. 5 (October 1991): 433–46. http://dx.doi.org/10.1097/00001813-199110000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Fay, Michael F., Richard Head, Peter Sminia, Nicholas Dowson, Leah Cosgrove, Stephen E. Rose, and Jenny H. Martin. "Valproate in Adjuvant Glioblastoma Treatment." Journal of Clinical Oncology 34, no. 25 (September 1, 2016): 3105–7. http://dx.doi.org/10.1200/jco.2016.67.2162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Slevin, M. L. "Adjuvant treatment for colorectal cancer." BMJ 312, no. 7028 (February 17, 1996): 392–93. http://dx.doi.org/10.1136/bmj.312.7028.392.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Aithal, G., and A. Tanner. "Adjuvant treatment for colorectal cancer." BMJ 312, no. 7043 (June 1, 1996): 1417. http://dx.doi.org/10.1136/bmj.312.7043.1417.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!